Drug Approval | January 24, 2024
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The workshop was conducted as a part of the NITI–State workshop series
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The company has received five final approvals
Sirius JV will be owned 51% by Sirius and 49% by Adani
US FDA approval based on NEURO-TTRansform Phase III results
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
